Lithium, administered to patients with bipolar disorders, is mainly excreted in the urine, and tubular reabsorption is involved. This study characterized the renal excretion of lithium in rats subjected to renal ischemia for 60 min or 90 min. After intravenous injection of lithium chloride at 25 mg/kg, the pharmacokinetic parameters of lithium were determined. In sham-operated rats, the renal clearance of lithium was calculated to be 1.49 ml/min/kg, and its ratio to creatinine clearance (fractional excretion) was 43.4%. Renal ischemia inhibited the renal excretion of lithium, and did not affect its fractional excretion. The urinary pH of rats with renal ischemia for 90 min was significantly higher than those of the other groups, and the linear regression with the fractional excretion of lithium in rats with renal ischemia showed a moderate correlation (r = 0.650, p = 0.00193). This study demonstrated the effect of renal ischemia on the renal excretion of lithium in rats. It was suggested that not only glomerular filtration but also the reabsorption of lithium was impaired by renal ischemia.
| INTRODUCTION
Lithium is used for treatment and prophylaxis for bipolar disorder.
Because the therapeutic range is narrow, its plasma concentration is measured in patients. Clinicians seem to regard steady-state concentrations of 0.6-1.2 mEq/l as optimal for maintenance treatment of bipolar disorders, and concentrations of 0.8-1.5 mEq/l as ideal for the acute management of manic episodes (Finley, Warner, & Peabody, 1995 ). Above a lithium plasma level of 1.0 mEq/l, various symptoms including tremor, lethargy, nausea, diarrhea, thirst, polyuria, confusion and seizure are observed (Finley et al., 1995; Price & Heninger, 1994) .
After oral administration, the ion shows almost complete bioavailability and it is predominantly excreted into urine. Approximately 75% of glomerular filtered lithium is reabsorbed in the proximal tubule (Finley et al., 1995) . To keep the plasma level of lithium in the therapeutic range, we pay attention to its reabsorption as well as the glomerular filtration, and sodium is the key for the renal handling of lithium. The reabsorption of lithium is influenced by sodium intake and several drugs including diuretics, angiotensin converting enzyme inhibitors and angiotensin II receptor blockers that affect the renal excretion of sodium (Finley et al., 1995; Thomsen & Schou, 1968) . It has been considered that sodium-hydrogen exchanger NHE3 mediates the reabsorption of lithium (Timmer & Sands, 1999 ), but we previously suggested the contribution of a sodium-phosphate cotransporter at a lower concentration than the clinical range in rats (Uwai et al., 2014; .
Recently, we examined the effect of each enantiomer of flurbiprofen, reported to increase the plasma concentration of lithium in patients with bipolar disorder (Hughes, Small, Brink, & McKenzie, 1997) , on the renal handling of lithium in rats. The (S)-enantiomer reduced creatinine clearance (C cr ) and the renal clearance of lithium (Li CL r ) in rats, and in particular, a significant decrease in the ratio of Li CL r to C cr was exhibited (Uwai, Matsumoto, Kawasaki, & Nabekura, 2017) . The findings suggested that the damage to glomerular filtration by (S)-flurbiprofen was greater than that to lithium reabsorption in the rats, and we considered it important to collect data regarding the renal handling of lithium in rats with various renal failures. This study examined the renal excretion of lithium in rats after renal ischemia. The obtained results indicated that the effect of renal ischemia on the renal handling of lithium was distinct from that of (S)-flurbiprofen. Gakuin University. Seven-week-old male Wistar/ST rats were from Chubu Kagaku Shizai (Nagoya, Japan), and were randomly divided into three groups: sham-operated rats, and rats treated with renal ischemia for 60 min (60 min-RI) and 90 min (90 min-RI). The animals were caged for 1 or 2 days in an isolator and a 12 h light-dark cycle at 25°C in a room of the School of Pharmacy, Aichi Gakuin University. Rats were fed normal pellet food ad libitum, and given water freely. The rats were anesthetized with ethyl carbamate and α-chloralose. Then a midline incision was made and renal ischemia was induced by the application of clamps across the renal artery and vein in both kidneys for the time periods. After releasing the clamps, restoration of renal blood flow was visually recognized. Sham-operated animals were subjected to identical treatment, except for the clamp application.
| Lithium pharmacokinetic experiments using rats
The lithium pharmacokinetic experiment was performed according to our previous report . Briefly, catheters were inserted into the femoral artery and femoral vein with polyethylene tubes (SP-31; Natsume Seisakusho, Tokyo, Japan) filled with heparin solution (50 IU/ml) for blood sampling and drug administration, respectively. Urine was collected from the urinary bladder catheterized with SP-31 polyethylene tubes. To maintain a sufficient and constant urine flow, 5% mannitol in saline was infused at 0.03 ml/min until the last blood sampling, after injection as a bolus at 2.5 ml/kg. Lithium chloride (Wako Pure Chemical Industries, Osaka, Japan) was dissolved in saline, and was intravenously injected as a bolus at 25 mg/kg, after a sufficient urine volume was detected. Blood was collected at 1, 2, 5, 10, 30 and 60 min after the lithium administration, and centrifuged for plasma sampling. Bladder urine samples were collected every 20 min after the lithium administration until the last blood sampling.
It took up to 200 min between the start of renal ischemia and the end of the lithium pharmacokinetic experiment.
After being appropriately diluted with 0.1% nitric acid, the concentrations of lithium in plasma and urine were determined, using Agilent 280Z AA atomic absorption spectrometry (Agilent Technologies, Santa Clara, CA, USA). The area under the plasma concentration-time curve of lithium up to 60 min (AUC 60 ) was calculated using the trapezoidal rule method. The Li CL r was obtained by dividing the urinary volume to 60 min after the lithium injection by its AUC 60 .
The concentrations of creatinine in the last urine and plasma samples were determined using the assay kit by the Jaffé method from Wako Pure Chemical Industries (Osaka, Japan). The C cr was calculated by dividing the creatinine amounts excreted into the urine samples by its concentration in plasma. The fractional excretion of lithium was calculated by dividing the Li CL r by C cr . The values of pH in the last urine samples were determined using a pocket pH meter (Isfetcom, Saitama, Japan).
| Statistical analysis
Data were expressed as the mean ± SE, and were analysed by a oneway analysis of variance followed by Scheffé's test using KaleidaGraph (Synergy Software, Reading, PA, USA). Differences were considered significant at p < 0.05.
| RESULTS AND DISCUSSION
Renal ischemia significantly increased P cr , and reduced C cr , and time dependency was observed (Table 1) . This means that renal ischemia decreased the renal function of rats in this study. Although plasma at the midpoint of the urine collection interval should be used to determine C cr , blood was collected at the final point of urine sampling.
We assumed that the effect of the sampling time was negligible, but it is necessary to interpret the results with the lag of blood sampling.
Because we did not perform biological tests except for the plasma creatinine concentration and its clearance, we did not obtain information on other adverse events. Figure 1 represents the disposition of lithium in rats after renal ischemia. We previously examined the dose dependency of lithium elimination in rats , and a dose of lithium chloride of 25 mg/kg was selected to observe phenomena around the therapeutic plasma range of lithium in the present study. In the sham group, 15.9% of administered lithium was recovered in urine up to 60 min after the injection. Renal ischemia increased the plasma level of lithium, and delayed its renal excretion.
The pharmacokinetic parameters of lithium are summarized in Table 1 . The values of Li AUC 60 , Li CL r and the fractional excretion of lithium in the sham group were comparable to those in non-treated rats that had received the same dose in our former study . Renal ischemia reduced the Li CL r according to the duration of ischemia. No effect of renal ischemia on the fractional excretion of lithium was recognized, when compared with the control value. The fractional excretion of lithium in the 90 min-RI group was significantly higher than that in the 60 min-RI group. The difference in the fractional excretion of lithium might be linked to the finding that the Li AUC 60 of the 60 min-RI group was comparable to that of the 90 min-RI group.
This study estimated the fractional excretion of lithium using C cr instead of the glomerular filtration rate. Because renal tubular secretion contributes to the urinary excretion of creatinine, it should be taken into consideration that the effect of the renal ischemia on the glomerular filtration and tubular secretion of creatinine was not separately determined in this study.
No inverse proportional change in the plasma levels of lithium or creatinine with their renal clearance by the renal ischemia was observed. We previously showed that lithium was excreted into bile in rats, although the excreted amount into bile was lower than the amount into urine (Uwai, Kawasaki, & Nabekura, 2015) . One reason why the Li AUC 60 was not elevated by renal ischemia, as expected, is that the amount of lithium excreted in the bile might be increased by renal ischemia. In addition, the renal ischemia might affect the distribution volume of lithium and creatinine.
Clinically, it was reported that the clearance of lithium was not well correlated with C cr , although a strong correlation was observed with gentamicin, which is almost exclusively excreted into urine by glomerular filtration, and cefoxitin, predominantly secreted into urine by the organic anion transport system (Kampf, Schurig, Korsukewitz, & Brückner, 1981; Kirkpatrick, Duffull, & Begg, 1999; Yukawa, Nomiyama, Higuchi, & Aoyama, 1993) . This implies that the decline of the lithium reabsorption is not parallel with that of glomerular filtration in patients with renal failure. Our recent report indicated a decrease of the fractional excretion of lithium as well as C cr by (S)-flurbiprofen in rats (Uwai et al., 2017) . This suggests a lesser impairment of lithium reabsorption in comparison with the glomerular filtration in rats administered (S)-flurbiprofen. The present study shows an unchanged fractional excretion of lithium in rats with renal ischemia (Table 1 ), meaning that renal ischemia gave similar degrees of dysfunction to the glomerular filtration and the reabsorption of lithium. Our animal studies also indicate heterogeneity in the effects of renal failure on the renal handling of lithium.
NHE3 is one of the candidates responsible for the reabsorption of lithium (Timmer & Sands, 1999) . It was reported that renal ischemia reduced the expression of NHE3 in the rat kidney (Di Sole et al., 2011; Wang, Rabb, Haq, Shull, & Soleimani, 1998) . Although NHE3 expression was not shown in the present study, we measured the urinary pH of rats after renal ischemia (Table 1) The urine samples for 20 min were collected until 60 min after the lithium injection. The lithium concentration in the bladder urine was determined, and the cumulative amounts excreted into urine were calculated. Each point represents the mean ± SE of 9-10 rats.
was observed between the sham group and the 60 min-RI group, but the urinary pH in the 90 min-RI group was significantly higher than those in the other groups. From this finding, a reduced function of NHE3 was speculated in the rats with renal ischemia for 90 min, and this might lead to the unchanged fractional excretion of lithium (Table 1) . Because the increase of the fractional excretion of lithium was seen in the 90 min-RI group compared with that in the 60 min-RI group (Table 1) , we plotted the relationship between the fractional excretion of lithium and urinary pH in the two renal ischemia groups (Figure 1c) . Their linear regression showed a moderate correlation (r = 0.650, p = 0.00193). The addition of plots of the sham rats deteriorated the correlation (r = 0.515, p = 0.00429). During the decline in renal function by ischemia, urinary pH might be a biomarker reflecting the lithium reabsorption. The urinary NHE3 is accepted as a biomarker of acute kidney injury (Siew, Ware, & Ikizler, 2011) . It would be interesting to examine urinary NHE3 in rats subjected to renal ischemia as well as its expression level in the kidney cortex.
In conclusion, this study reveals the effect of renal ischemia on the renal handling of lithium in rats.
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